Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

NRIX Interest Expense

Cost of servicing the company's debt during the period.

Nurix Therapeutics, Inc.NASDAQ: NRIX

Interest Expense · Q3 FY2026 · quarter ended Aug 2026

Interest expense remains negative

Q3 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterAug 2026
$0— QoQ
Last fiscal yearNov 2025
$0— YoY
LTMAug 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How NRIX compares with its peers on the latest reported figures

  • NRIX's LTM Aug 2026 interest expense of $0 is the 6th highest of the 8 companies compared; the peer median is $1.47M.
  • Interest expense amounts to 0.0% of revenue for NRIX, versus a peer median of 2.0%.
NRIX Competitors Peer median
Interest Expense for NRIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$80.69M +524.3%+120.8%37.2%
RVMDRevolution Medicines, Inc.LTM Jun 2026$59.34M ———
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$6.9M -12.6%+25.5%2.3%
KURAKura Oncology, Inc.LTM Mar 2026$1.47M -8.5%+87.6%2.0%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$211K -29.4%+12.3%0.2%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 ——0.0%
TNGXTango Therapeutics, Inc.LTM Sep 2026$0 ———
CCCCC4 Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding NRIX) $1.47M-10.6%+56.5%2.0%

Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Revenue29.75M38.63M76.99M54.55M83.98M
Cost of Revenue116.43M184.5M189.15M221.63M18.86M
Gross Profit(86.68M)(145.87M)(112.16M)(167.08M)65.12M
Gross Margin-291.4%-377.6%-145.7%-306.3%77.5%
Research & Development116.43M184.5M189.15M221.63M308.16M
Selling, General & Admin31.2M38M42.9M45.94M52.74M
Operating Expenses31.2M38M42.9M45.94M350.79M
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
EBITDA(110.98M)(169.55M)(130.29M)(176.87M)(244.84M)
EBITDA Margin-373.0%-438.9%-169.2%-324.2%-291.5%
Operating Income(117.89M)(183.87M)(155.06M)(213.03M)(285.67M)
Operating Margin-396.3%-476.0%-201.4%-390.5%-340.2%
Interest Income823K3.51M11.12M19.73M21.97M
Interest Expense00000
Other Income / Expenses823K3.51M11.12M19.73M21.97M
Income Before Tax(117.06M)(180.36M)(143.95M)(193.3M)(263.7M)
Pre-Tax Margin-393.5%-466.9%-187.0%-354.4%-314.0%
Income Tax Expense131K00270K760K
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Net Margin-393.9%-466.9%-187.0%-354.9%-314.9%
EPS (Basic)(2.73)(3.71)(2.65)(2.88)(3.05)
EPS (Diluted)(2.73)(3.71)(2.65)(2.88)(3.05)
Weighted Avg Shares42.9M48.61M54.34M67.12M86.67M
Weighted Avg Shares (Diluted)42.9M48.61M54.34M67.12M86.67M

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.